HUP0105407A3 - Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates - Google Patents
Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediatesInfo
- Publication number
- HUP0105407A3 HUP0105407A3 HU0105407A HUP0105407A HUP0105407A3 HU P0105407 A3 HUP0105407 A3 HU P0105407A3 HU 0105407 A HU0105407 A HU 0105407A HU P0105407 A HUP0105407 A HU P0105407A HU P0105407 A3 HUP0105407 A3 HU P0105407A3
- Authority
- HU
- Hungary
- Prior art keywords
- triazolo
- intermediates
- preparation
- pharmaceutical compositions
- quinolin derivatives
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- OCSVDRXXLBXUJM-UHFFFAOYSA-N triazolo[1,5-a]quinoline Chemical class C1=CC=C2N3N=NC=C3C=CC2=C1 OCSVDRXXLBXUJM-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
Priority Applications (28)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0105407A HUP0105407A3 (en) | 2001-12-21 | 2001-12-21 | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
KR1020047009789A KR100934796B1 (ko) | 2001-12-21 | 2002-12-17 | 아데노신 수용체 리간드로서 유용한 트리아졸로-퀴놀린유도체 |
EA200400848A EA007066B1 (ru) | 2001-12-21 | 2002-12-17 | Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов |
IL16244402A IL162444A0 (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
US10/499,250 US7365089B2 (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
BR0215276-2A BR0215276A (pt) | 2001-12-21 | 2002-12-17 | Derivados de triazolo-quinolina úteis como ligandos receptores de adenosina |
EP02788260A EP1456204A1 (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
CNB028256468A CN1307175C (zh) | 2001-12-21 | 2002-12-17 | 用作腺苷受体配体的三唑并喹啉衍生物 |
JP2003554684A JP4724366B2 (ja) | 2001-12-21 | 2002-12-17 | アデノシン受容体リガンドとして有用なトリアゾロ−キノリン誘導体 |
UA20040706067A UA79955C2 (en) | 2001-12-21 | 2002-12-17 | Triazolochinoline derivatives as ligands of adenosine receptors |
NZ534016A NZ534016A (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
MXPA04006113A MXPA04006113A (es) | 2001-12-21 | 2002-12-17 | Derivados de triazoloquinolina utiles como ligandos receptores de adenosina. |
HU0402282A HUP0402282A3 (en) | 2001-12-21 | 2002-12-17 | Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
PCT/HU2002/000143 WO2003053968A1 (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
YU56004A RS56004A (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
PL02370747A PL370747A1 (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
CA2470064A CA2470064C (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
AU2002353240A AU2002353240B2 (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
MEP-188/08A MEP18808A (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
MA27724A MA27094A1 (fr) | 2001-12-21 | 2004-06-07 | Derives triazolo-quinoline utiles en tant que ligands recepteurs d'adenosine. |
TNP2004000106A TNSN04106A1 (en) | 2001-12-21 | 2004-06-08 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
IL162444A IL162444A (en) | 2001-12-21 | 2004-06-10 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
IS7318A IS7318A (is) | 2001-12-21 | 2004-06-16 | Tríasól-kínólínafleiður sem eru gagnlegar sem adenósínviðtakabindlar |
ZA200404802A ZA200404802B (en) | 2001-12-21 | 2004-06-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands. |
NO20043119A NO329757B1 (no) | 2001-12-21 | 2004-07-20 | Triazolokinolinderivater som kan anvendes som adenosinreseptorligander, fremgangsmate for fremstilling derav, mellomprodukter i fremgangsmaten, farmasoytiske preparater som inneholder forbindelsene og anvendelse av forbindelsene til fremstilling av farmasoytiske preparater |
HR20040672A HRP20040672A2 (en) | 2001-12-21 | 2004-07-20 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
US12/039,272 US7713992B2 (en) | 2001-12-21 | 2008-02-28 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
JP2010200550A JP2011042653A (ja) | 2001-12-21 | 2010-09-08 | アデノシン受容体リガンドとして有用なトリアゾロ−キノリン誘導体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0105407A HUP0105407A3 (en) | 2001-12-21 | 2001-12-21 | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0105407D0 HUP0105407D0 (en) | 2003-02-28 |
HUP0105407A2 HUP0105407A2 (hu) | 2003-10-28 |
HUP0105407A3 true HUP0105407A3 (en) | 2004-04-28 |
Family
ID=90001529
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0105407A HUP0105407A3 (en) | 2001-12-21 | 2001-12-21 | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
HU0402282A HUP0402282A3 (en) | 2001-12-21 | 2002-12-17 | Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0402282A HUP0402282A3 (en) | 2001-12-21 | 2002-12-17 | Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
Country Status (23)
Country | Link |
---|---|
US (2) | US7365089B2 (hu) |
EP (1) | EP1456204A1 (hu) |
JP (2) | JP4724366B2 (hu) |
KR (1) | KR100934796B1 (hu) |
CN (1) | CN1307175C (hu) |
AU (1) | AU2002353240B2 (hu) |
BR (1) | BR0215276A (hu) |
CA (1) | CA2470064C (hu) |
EA (1) | EA007066B1 (hu) |
HR (1) | HRP20040672A2 (hu) |
HU (2) | HUP0105407A3 (hu) |
IL (2) | IL162444A0 (hu) |
IS (1) | IS7318A (hu) |
MA (1) | MA27094A1 (hu) |
MX (1) | MXPA04006113A (hu) |
NO (1) | NO329757B1 (hu) |
NZ (1) | NZ534016A (hu) |
PL (1) | PL370747A1 (hu) |
RS (1) | RS56004A (hu) |
TN (1) | TNSN04106A1 (hu) |
UA (1) | UA79955C2 (hu) |
WO (1) | WO2003053968A1 (hu) |
ZA (1) | ZA200404802B (hu) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
HUP0400812A2 (en) * | 2004-04-19 | 2006-02-28 | Sanofi Aventis | Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
US20050288502A1 (en) * | 2004-06-25 | 2005-12-29 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
CN102702314A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdfyigsr、制备和应用 |
CN102702312A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdvyigsk、制备和应用 |
CN102702315A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdsyigsk、制备和应用 |
CN102702313A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdvyigsr、制备和应用 |
CN102702316A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdfyigsk、制备和应用 |
HUP0700395A2 (en) * | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DK2950649T3 (da) | 2013-02-01 | 2020-05-04 | Wellstat Therapeutics Corp | Aminforbindelser med antiinflammations-, antisvampe-, antiparasit- og anticanceraktivitet |
CN108358927B (zh) * | 2018-01-26 | 2020-09-01 | 郑州大学 | 1,4-二取代1,2,3-三氮唑核苷类似物及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE280110C (hu) | ||||
DE280109C (hu) | ||||
GB1479759A (en) * | 1974-11-23 | 1977-07-13 | Lepetit Spa | Heterocyclic fused derivatives of indole and quinoline |
DD280110A1 (de) * | 1989-02-22 | 1990-06-27 | Univ Berlin Humboldt | Verfahren zur herstellung von 1.2.4-triazolo/1.5-a/-pyridin-8-carbonitrilen |
DD280109A1 (de) * | 1989-02-22 | 1990-06-27 | Univ Berlin Humboldt | Verfahren zur herstellung substituierter 1.2.4-triazolo/1.5-a/-pyridine |
DE3926770A1 (de) | 1989-08-12 | 1991-02-14 | Basf Ag | (1,2,4)triazolo(1,5-a)pyridine |
US6066642A (en) * | 1996-01-29 | 2000-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists |
US5780481A (en) * | 1996-08-08 | 1998-07-14 | Merck & Co., Inc. | Method for inhibiting activation of the human A3 adenosine receptor to treat asthma |
US6448253B1 (en) * | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
-
2001
- 2001-12-21 HU HU0105407A patent/HUP0105407A3/hu unknown
-
2002
- 2002-12-17 UA UA20040706067A patent/UA79955C2/uk unknown
- 2002-12-17 EP EP02788260A patent/EP1456204A1/en not_active Withdrawn
- 2002-12-17 RS YU56004A patent/RS56004A/sr unknown
- 2002-12-17 IL IL16244402A patent/IL162444A0/xx unknown
- 2002-12-17 PL PL02370747A patent/PL370747A1/xx not_active Application Discontinuation
- 2002-12-17 AU AU2002353240A patent/AU2002353240B2/en not_active Ceased
- 2002-12-17 CN CNB028256468A patent/CN1307175C/zh not_active Expired - Fee Related
- 2002-12-17 CA CA2470064A patent/CA2470064C/en not_active Expired - Fee Related
- 2002-12-17 EA EA200400848A patent/EA007066B1/ru not_active IP Right Cessation
- 2002-12-17 BR BR0215276-2A patent/BR0215276A/pt not_active IP Right Cessation
- 2002-12-17 HU HU0402282A patent/HUP0402282A3/hu unknown
- 2002-12-17 NZ NZ534016A patent/NZ534016A/en not_active IP Right Cessation
- 2002-12-17 KR KR1020047009789A patent/KR100934796B1/ko not_active IP Right Cessation
- 2002-12-17 US US10/499,250 patent/US7365089B2/en not_active Expired - Fee Related
- 2002-12-17 MX MXPA04006113A patent/MXPA04006113A/es active IP Right Grant
- 2002-12-17 JP JP2003554684A patent/JP4724366B2/ja not_active Expired - Fee Related
- 2002-12-17 WO PCT/HU2002/000143 patent/WO2003053968A1/en active IP Right Grant
-
2004
- 2004-06-07 MA MA27724A patent/MA27094A1/fr unknown
- 2004-06-08 TN TNP2004000106A patent/TNSN04106A1/en unknown
- 2004-06-10 IL IL162444A patent/IL162444A/en not_active IP Right Cessation
- 2004-06-16 IS IS7318A patent/IS7318A/is unknown
- 2004-06-17 ZA ZA200404802A patent/ZA200404802B/en unknown
- 2004-07-20 NO NO20043119A patent/NO329757B1/no not_active IP Right Cessation
- 2004-07-20 HR HR20040672A patent/HRP20040672A2/xx not_active Application Discontinuation
-
2008
- 2008-02-28 US US12/039,272 patent/US7713992B2/en not_active Expired - Fee Related
-
2010
- 2010-09-08 JP JP2010200550A patent/JP2011042653A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303350A3 (en) | Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions | |
HUP0204410A3 (en) | Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
IL161693A0 (en) | N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | |
HUP0401292A3 (en) | Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof | |
HUP0200207A3 (en) | Substituted 2-aryl-3-(hetroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compositions and methods for their preparation | |
HUP0401083A3 (en) | 4-amino-6-phenyl-pyrrolo [2,3-d] pyrimidine derivatives, pharmaceutical compositions containing them and process for the preparation of the compounds | |
IL191960A (en) | History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them | |
HUP0202103A3 (en) | 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives, their use, pharmaceutical compositions containing them, process for the preparation of the compounds and intermediates | |
HUP0203052A3 (en) | Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
IL176385A (en) | Compressed history of pyrrolo [34, -c] carbazol-1-van and pyrrolo [34, -c] carbazol-3,1-discussion and pharmaceutical preparations containing them | |
HUP0104762A3 (en) | Pharmaceutical moxifloxacin compositions and process for their preparation | |
HUP0402018A3 (en) | 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them | |
HUP0003826A3 (en) | Novel triazolo [4,5-b] pyrimidine derivatives, process for their preparation and pharmaceutical compositions thereof | |
HUP0203140A3 (en) | Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0204563A3 (en) | Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions | |
HUP0105407A3 (en) | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates | |
HUP0202624A3 (en) | Pyrazolo[4,3-d]pyrimidine-derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0105054A3 (en) | Imidazo[4,5-c]-pyridine-4-on-derivatives, pharmaceutical compositions containing them and process for their preparation | |
HUP0003118A3 (en) | Use of 2,7-substituted octahydro-1h-pyrido [1,2-a]pyrazine derivatives for production of pharmaceutical compositions | |
HUP0400317A3 (en) | Beta-carboline derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
HU0103075D0 (en) | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one derivatives and intermediates thereof | |
HUP0105406A3 (en) | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates | |
IL147248A0 (en) | Naphthyridine derivatives, process for their preparation, their use and pharmaceutical compositions comprising them | |
HUP0202282A3 (en) | Novel octahydro-2h-pyrido[1,2-a]pyrazine compounds, process for their preparation and pharmaceutical compositions containing them | |
HU0003979D0 (en) | Process for the preparation of 3-pyridylsulphonil-pyrazolo[4,3-d] pyrimidin-7-one derivatives and intermediates thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |